Hodgkin Lymphoma: What are My Treatment Options in 2024? – Registration
Sign up for instant access to the replay video!
Brought to you in partnership with The Leukemia & Lymphoma Society & Imerman Angels
Discussion details
Key topics:
- Clinical Trials & Treatment
- Updates on the latest available trials
- Monoclonal antibody treatments like brentuximab
- AHOD2131 and strategies to re-sensitize to PD1 inhibitors
- Ways to minimize side effects from treatments
- Advances in Post-Transplant Relapse
- CAR T-Cell Therapy and bispecific antibodies
- Early vs Advanced Stage Advancements
- Trials like SWOG S1826, with an emphasis on the potential standardization of Nivolumab in frontline advanced-stage cases
- Addressing Treatment Gaps
- Enhancing frontline treatment and managing patients’ refractory to specific therapies
- Developments in Salvage Therapy
- Pembro + GVD and Nivolumab + ICE
Past Hodgkin Events
Special thanks again to Pfizer for its support of our independent patient education content. The Patient Story retains full editorial control.
This interview has been edited for clarity and length. This is not medical advice. Please consult with your healthcare provider for treatment decisions.